Jade Biosciences price target raised to $35 from $25 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Jade Biosciences (JBIO) to $35 from $25 and keeps a Buy rating on the shares following the Q4 report. The firm increased the gross price for JADE101 to $390,000 per patient per year, from $200,000, after Otsuka priced sibeprenlimab at $390,000 per patient per year. The analyst believes JADE101’s pharmacokinetic and pharmacodynamic profiles “could be the main focus of the upcoming readout.”